Hints and tips:
Related Special Reports
...Emma Walmsley, chief executive of AstraZeneca’s British rival GSK, earned £12.7mn in 2023....
...Historic problems also continue to dog GSK....
...It’s tantamount to what the Nazis did,” said Francis Timmons, a councillor in south Dublin, referring to medical experiments in concentration camps during the second world war....
...ITM Power has revealed half-year figures that suggest its turnaround plan is having the desired effect....
...The WHO first recommended the GSK shot in 2021 for widespread use. In October, the WHO also gave its backing to the Oxford vaccine. The plan faces logistical challenges....
...The £64bn company has long lagged behind £168bn Anglo-Swedish rival AstraZeneca, with investors raising questions over GSK’s pipeline of products and its growth plans....
...The medical tourism component was “creative”, he added, emphasising that the key was to make “a live rhino worth more than a dead rhino”....
...The company has been working with the pharmaceutical giant GSK, focusing on immuno-oncology drugs....
...GSK has announced plans to sell down its stake in consumer health company Haleon, selling about 2.9 per cent of the Panadol maker’s issued share capital....
...Thames Water on Monday updated its business plan to increase the amount it plans to spend on its network to combat environmental issues such as sewage spills by £1.1bn to £19.8bn....
...Haleon was born as a joint venture between Pfizer and GSK in 2019 that sat within GSK, before it was spun off via a UK listing in 2022, leaving GSK and Pfizer with 13.5 per cent and 32 per cent of the business...
...GSK’s Nigeria affiliate also scaled back its business last year, shutting down the distribution of its own medicines and switching to third-party Nigerian companies....
...GSK said it was working with advisers to determine the next steps and is aiming to submit a plan to Nigeria’s Securities and Exchange Commission....
...The Centers for Medicare & Medicaid Services said last month that Medicare Part D drug benefit plans will cover weight loss medicines when they are approved to treat a separate medical problem, such as heart...
...If it succeeds in a phase-3 trial, the vaccine candidate, dubbed IVX-A12, would compete with approved RSV shots from GSK and Pfizer, and potentially one from Moderna....
...It plans to invest about $25bn in research and development from 2024 to 2028....
...“The biggest barrier is insurance companies,” said Lawrence Honig, a neurologist at New York’s Columbia University Irving Medical Center....
...Yet Netanyahu has presented no clear plan about who will administer Gaza or maintain civil order. Still, the IDF insists the battle at al-Shifa represents its war plan in action....
...But Walmsley has struggled to convince many investors that her plan is working and the share price was dragged down last year by concerns about the potential cost of lawsuits over the heartburn drug Zantac...
...“We will set out a full implementation plan following careful consideration of this final report and its recommendations,” said NHS England....
...The four pharmaceutical companies that part-funded the project — Amgen, AstraZeneca, GSK and Johnson & Johnson, — received nine months’ exclusive access to the data, which will now be made available to approved...
...led risers in the Stoxx Europe 600 index, up 8.6 per cent after strong first-quarter sales and following release of its latest strategic plan....
...Thomas Breuer, chief global health officer at GSK, hailed an “entirely novel approach for malaria control”....
...Some patients were turned away and surgeries postponed as doctors walked off their jobs this week in protest against government plans to increase medical school admissions to address the shortage of physicians...
...Biden’s physical examination also came on the same day that Mitch McConnell, the Republican senator from Kentucky, announced his plan to step down as the party’s leader in the Senate in November....
International Edition